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ABSTRACT
Objective: One of the existing methods to assess the transferability of
economic evaluations is the model of Welte, which is a decision-chart
method that includes general and speciﬁc knockout criteria and a transfer-
ability checklist. This study aims to testWelte’smodelwith the help of a case
study.
Methods: In this study, foreign studies were transferred to TheNetherlands
and then compared with a Dutch reference study. In the case study, the
cost-effectiveness of physiotherapy was compared with a multidisciplinary
treatment.With the help of a systematic search, several foreign studies could
be identiﬁed. Based on these foreign studies, two different predictions were
produced for The Netherlands. In the “all studies prediction,” all foreign
studies were used. In the “Welte’s model prediction,” only the foreign
studies were used, which passed the general and speciﬁc knockout criteria.
Both predictions were compared with the Dutch reference case.
Results: A total of 14 non-Dutch studies were identiﬁed. Seven studies did
not pass the general knockout criteria and one study did not pass the
speciﬁc knockout criteria. As a result, 14 studies were included in the “all
studies prediction” and 6 studies in the “Welte’s model prediction.” The
predictions yielded different results and the “Welte’s model prediction”
proved better on costs than the “all studies prediction.”
Discussion: The application of Welte’s model does inﬂuence cost and
effects estimates when transferring economic data between countries.
However, more cases should be subjected to the Welte transferability
model before a ﬁnal conclusion can be drawn.
Keywords: case study, economic evaluation, model of Welte, testing, trans-
ferability.
Introduction
International interest in the economic evaluation of interventions
in health care is growing [1]. In recent years, economic evalua-
tions have become more decisive in the process of decision-
making in health care all over the world [2]. Using data,
methods, or results from published studies abroad can save time
compared to conducting a new economic evaluation in your own
country. When studies cannot be performed nationally, for
instance because of small number of patients in a country, it may
even be the only possibility. Decision-makers can use economic
evaluations in at least two ways: “uncorrected” by applying the
conclusions directly, or “corrected” by applying the methods and
data that are applicable and substituting local methods and data
for those that are not [3]. However, every country has its own
unique health-care structure. This raises the question whether the
results of economic studies can be transferred from one country
to another without any correction [2]. Transferability may be
deﬁned as the generalizability of study results from one policy
setting to another or from one country to another [4].
The extrapolation of the results of economic evaluations to
another setting is not straightforward [1]. Health technology
assessment researchers agree about the most important factors
that inﬂuence the transferability of study results [1–6]. These
factors are: demography of the population, epidemiology of
diseases, availability of health-care resources and variations in
clinical practice, incentives to health-care professionals and insti-
tutions, relative prices, and population preferences [4]. Besides
that, cost-effectiveness results for pharmaceuticals vary between
Western European countries and these variations are not system-
atic. One of the main causes appeared to be the price of the major
cost drivers. However, the main factor is whether resource use is
allowed to vary across countries and, therefore, analysts should
provide strong arguments for pooling resource use data [7]. These
factorsmake a complete extrapolation of results from one country
to another impossible [1].
The transferability factors also hinder the transfer of an incre-
mental cost-effectiveness ratio (ICER) without any adjustments,
because it is assumed that the costs always differ between coun-
tries. These differences can be associated with differences in
health-care consumption and prices. Therefore, the cost data
should always be adjusted to the decision country. The effective-
ness data may be transferable from place to place. This is due to
the assumption that the differences in outcome resulting from
interventions between patients in countries are small and, there-
fore, the effectiveness of treatments is the same [4,8].
In the last 15 years, much has been written about these
factors inﬂuencing the transferability, but the discussion
remained rather theoretical. To our knowledge, this study is one
of the ﬁrst to test the theoretical transferability factors in an
experimental setting. By testing the theoretical assumptions, the
pitfalls and problems related to the transfer of studies to other
settings will be identiﬁed.
One of the existing methods to assess the transferability of
economic evaluations is themodel ofWelte. The other existing and
published methods to assess the transferability are those of
Boulenger et al. [3], Urdahl et al. [9], and Nixon et al. [10]. The
methods of Boulenger et al. [3] and Nixon et al. [10] have no clear
cutoff points to decide if the economic evaluation is transferable
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or not. The method of Urdahl et al. [9] is especially developed for
assessing method-based economic evaluations. Welte’s model was
chosen because it has clear cutoff points and can be used for the
assessment of both empirical and method-based economic evalu-
ations. The research question is: To which extent is Welte’s model
a valid method to assess the transferability of economic evalua-
tions? Consequently, the objective of this study is to test Welte’s
model. This testing will be carried out by means of a case study.
Theory: Short Description ofWelte’s Model
The model of Welte is one of the ﬁrst general and the oldest
method that is developed to decide which studies are transferable
[6]. Before Welte’s model, only models for speciﬁc diseases were
available, cf. Caro et al. (1999) [11]. Welte’s model is a transfer-
ability decision-chart method that includes general and speciﬁc
knockout criteria and a transferability checklist. With the help of
these general and speciﬁc knockout criteria, it is possible to
determine which studies can be transferred to the decision
country and which cannot. A study or article must ﬁrst meet
three general knockout criteria: 1) the evaluated technology
should be comparable with the one that shall be used in the
decision country; 2) the comparator should be comparable to the
one that is relevant to the decision country; and 3) the study
should possess an acceptable quality. When a study has passed
these general knockout criteria, the speciﬁc knockout criteria will
be used to determine which parts of the studies are transferable.
The speciﬁc knockout criteria are listed in Table 1.
These factors or speciﬁc knockout criteria in the transferabil-
ity checklist are used to determine the correspondence between
the study country and the decision country. This is carried out in
three steps. First, the relevance of each transferability factor is
determined. In the second step, the level of correspondence
between the study country and the decision country is estimated.
For the last step, the checklist is applied to determine the
expected effect of the factor on the cost-effectiveness ratio (CER).
The estimation of the CER depends on the relevance of the
factors and the correspondence between the study and decision
country. When both are high, the estimation will be unbiased. In
the case of a low correspondence, the estimation of the CER will
be biased. After these three steps, it can be decided which adjust-
ments are necessary to transfer the foreign studies [6].
Methods
Case Selection
To test Welte’s model, a case was selected by following the next
steps. First, the topic for the case was searched for using
MEDLINE, whereby the topic of the case study should fulﬁll the
following criteria: cost-beneﬁt-analysis [mesh], study not older
than 5 years (py > 2002), randomized controlled trial (rand* in ti
or rand* in ab or rct in ab or rct in ti), incremental comparison
of treatments (differen* in ti or differen* in ab or increment* in
ti or increment* in ab or rati* in ti or rati* in ab), societal
perspective (soci* in ti or soci* in ab or indir* in ti or indir* in
ab or non-medi* in ti or non-medi* in ab), and cost-utility
analysis (util* in ab or util* in ti). These search criteria resulted
in 74 results, whereby the abstracts were checked if they fulﬁlled
the following criteria: fulﬁlled the criteria of the MEDLINE
search, performed in The Netherlands, only empirical and no
modeling studies, and only single-country studies.
Only a limited number of Dutch studies satisﬁed these criteria
(N = 15). The full text of the articles were read, and based on
these articles, any study indicating that it was the ﬁrst economic
evaluation on this topic was considered unsuitable and removed.
For the remaining studies (N = 9), MEDLINE was searched to
ﬁnd comparable foreign studies, which had to be at least ﬁve
foreign studies for each topic. The foreign studies should fulﬁll
the same criteria as the Dutch study, but there were some extra
requirements, namely: equal disease, article should be written in
English, study performed outside The Netherlands, studies per-
formed in different foreign countries, and “comparable” inter-
vention or experimental treatment. Studies were excluded if they
were multinational trials. Based on this search strategy, only one
case study remained, namely the study of Van der Roer, Van
Tulder, Van Mechelen, et al. (2008) [12] (Table 2).
Based on Dutch guidelines for costing research, a description
of the necessary data was produced, while at the same time, a
search for suitable foreign studies was performed [8]. The foreign
studies have mainly been identiﬁed by looking at three systematic
reviews [27–29]. Furthermore, a systematic search was per-
formed within the electronic databases MEDLINE, PubMed, and
Econlit, and in the most relevant journals, Spine and Pain. The
following search strategy was used: low back pain [mesh] AND
costs and cost analysis [mesh]; low back pain AND physical
therapy [mesh] OR exercise* [tw] AND costs and cost analysis;
low back pain AND pain clinics [mesh] OR cognitive therapy
[mesh] OR multidisciplinary treatm* [tw] AND clinical trial
[mesh]; low back pain AND pain clinics OR cognitive therapy
AND costs, and cost analysis OR effect* [tw]. All references were
subsequently checked to identify additional studies.
Making the Predictions
In the next step, the studies were assessed on their transferability
to The Netherlands. This was carried out with the help of Welte’s
model as described in the theory section. The third general
knockout criterion states that the studies should possess an
acceptable quality. The criteria list “consensus on health eco-
nomic criteria” (CHEC) was utilized to assess the methodologi-
cal quality of the foreign studies [30]. By applying the general
knockout criteria, each treatment arm of a foreign study was
separately examined to decide if the treatment arm could pass the
criteria. In theory, it is possible that one of the treatment arms
passes the general knockout criteria and that the other treatment
arm does not pass the general knockout criteria. All studies were
assessed on the transferability of the data by two different
reviewers. The corresponding author (SK) reviewed all articles,
and the three other authors (AA, SE, and JS) divided the assess-
ment of the studies among them.
After the assessments, two different predictions were pro-
duced and both predictions were based on the same model. The
main structure of the model is given in Table 3. We distinguished
three different costs groups, namely the intervention costs
Table 1 Speciﬁc knockout criteria of Welte’s model
Transferability factors Factors
Methodological characteristics perspective*; discount rate; medical cost
approach*; productivity cost approach*
Health-care characteristics absolute and relative prices; practice
variation; technology availability
Population characteristics incidence/prevalence; case-mix; life
expectancy; health-status preference;
acceptance, compliance and incentives to
patients; productivity and work-loss time*;
disease spread
*These factors have a high relevance in this study.
Source:Welte et al. [6].
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(Ci = qi ¥ pi), sick leave (Csl) and other health-care consumption
(Ch). The costs of the multidisciplinary treatment itself were
represented by Cmdt and of physiotherapy by Cphysio. The effect of
the treatments was expressed in quality-adjusted life-years
(QALYs).
To make the two predictions, data were extracted from the
foreign studies. In the “all studies prediction,” all foreign studies
were used. In the “Welte’s model prediction,” all studies that
passed the general and speciﬁc knockout criteria, and were there-
fore considered to be transferable, were used. The predictions
were produced according to the Dutch guidelines for costing
research [8].
Because of differences in relative prices between countries, it
is not possible to transfer prices [4,8]. As a result, all foreign
prices were replaced by Dutch prices. All the available quantity
data were pooled using the averages of all foreign studies and the
Dutch prices were attached to these average quantities. In some
cases, the prices of rehabilitation centers were used to estimate
the real costs. For all other costs, the real prices of that speciﬁc
treatment were used. All prices utilized, originating from 2003,
can be found in the Dutch guideline for costing research [8]. The
prices were adjusted to 2004 prices, because the Dutch study was
based on 2004 prices. The adjustment was carried out with the
help of the consumer price index of The Netherlands [31]. Next
to that, the effects of both the multidisciplinary treatment and
physiotherapy are calculated by looking at the change from
baseline.
Sensitivity analysis was performed to investigate the robust-
ness of the predictions. For both predictions, a high/low analysis
was performed with only the highest and the lowest values used.
This way, predictions with the lowest and the highest values of all
parameters were available for the “all studies prediction” and the
“Welte’s model prediction.” Furthermore, plots of the total costs
were produced to identify if the predictions and the results of the
Dutch study correspond with each other.
In the last step, the two predictions were compared with a
Dutch study on the same topic (Fig. 1).
Results
After a thorough search for a suitable case, the chosen case study
became subacute and chronic nonspeciﬁc low back pain. The
Dutch study that was chosen as reference case is the study of Van
der Roer (2008). In this study, the cost-effectiveness of physio-
therapy was compared with a multidisciplinary treatment that
included education, exercises, and behavioral treatment [12].
Transferability Check: General Knockout Criteria
As a result of the search for foreign studies, a total of 14 studies,
from which the references and the characteristics are shown in
Table 2 Selection of the case study
Step 1 Selection based on keywords
Search criteria Results
#1 cost-beneﬁt-analysis [mesh] 43206
#2 rand* in ti or rand* in ab or rct in ab or rct in ti 458732
#3 differen* in ti or differen* in ab or increment* in ti or increment*
in ab or rati* in ti or rati* in ab
3055267
#4 soci* in ti or soci* in ab or indir* in ti or indir* in ab or
non-medi* in ti or non-medi* in ab
500803
#5 #1 and #2 and #3 and #4 and (py > 2002) 252
#6 util* in ab or util* in ti 324129
#7 #5 and #6 74
Step 2 Exclusion based on abstract
Reason Number*
Studies did not fulﬁll selection criteria 37
Non-Dutch study 48
Modeling study 15
Nonempirical study 15
Multicountry study 5
*total number higher than 74 because of several possible reasons
Step 3 Exclusion based on full article
Reference Topic Reason for removal
Onrust (2008) [13] visiting service for older widowed individuals no other economic evaluations
Van den Hout (2008) [14] treatments for sciatica from lumbar disc herniation no other trial-based economic evaluations
Bulthuis (2008) [15] exercise therapy by hospital discharged arthritis patients only Dutch economic evaluations
Zijlstra (2007) [16] spa treatment for ﬁbromyalgia no comparable studies
Oude Voshaar (2006) [17] tapering off benzodiazepines no other economic evaluations
Korthals-de Bos (2006) [18] treatments for carpal tunnel syndrome no other trial-based economic evaluations
Steenstra (2006) [19] back to work program for workers with low back pain only one other economic evaluation
Van den Hout (2005) [20] treatment programs for rheumatoid arthritis only foreign effect studies
Van den Hout (2005) [21] mobilization techniques for adhesive capsulitis no other economic evaluations
Korthals-de Bos (2004) [22] interventions for lateral epicondylitis no other economic evaluations
Van Dieten (2003) [23] pharmaceutical treatments for reﬂex sympathetic dystrophy no other economic evaluations for this treatment
Van den Hout (2003) [24] radiotherapy for painful bone metastases no foreign economic evaluations
Van den Hout (2003) [25] multidisciplinary care for rheumatoid arthritis no other economic evaluations
Korthals-de Bos (2003) [26] treatments for neck pain not enough foreign economic evaluations
Table 3 Main structure of the model
ICER = DC/DE
DC = Ce - Cc
DE = Ee - Ec
E = Eqaly
C = Ci + Ch + Csl
Ch = (qgp ¥ pgp) + (qit ¥ pit) + (qth ¥ pth) + (qopd ¥ popd) + (qha ¥ pha) + (qm ¥ pm)
Ce, total costs of experimental treatment; Cc, total costs of control treatment; Ci, total costs
of intervention; Ch, costs of health-care consumption; Csl, costs of sick leave; Ee, effect of
experimental treatment; Ec, effect of control treatment; p, price; q, quantity; qaly, quality-
adjusted life-years; gp, general practitioner; it, imaging techniques; th, physiotherapist;
opd, outpatient department visit; ha, hospital admission; m, medicine use.
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Table 4, were identiﬁed. In all studies, the cost-effectiveness or
effectiveness of either physiotherapy or the multidisciplinary
treatment was determined. The multidisciplinary treatment was
deﬁned as the evaluated technology and physiotherapy as the
comparator. A study was considered to be of low quality if it
scored 10 or lower out of the possible 19 on the CHEC criteria
list [30].
Seven studies, from which the references can be seen in
Table 3, did not fulﬁll the general knockout criteria. The studies
of Cherkin et al. (2001) [32] and Wright et al. (2005) [40] did
not fulﬁll the ﬁrst and the third general knockout criteria. In the
studies of Karjalainen et al. (2003, 2004) [34,35], Molde Hagen
et al. (2000) [37], and Molde Hagen et al. (2003) [37], the right
evaluated technology was not available. The studies of Cherkin,
et al. (1998) [33], Klaber Moffet et al. (1999) [36], and Tor-
stensen et al. (1998) [39] had not enough quality and did not
fulﬁll the third criterion. After passing the general knockout
criteria, the speciﬁc knockout criteria were applied to the seven
studies that passed the general knockout criteria.
Transferability Check: Speciﬁc Knockout Criteria
The following factors were found to have a high relevance for
this particular case: perspective, medical cost approach, produc-
tivity cost approach, and productivity and work-loss time. All
studies in this case originate either from West European countries
or from the United States. Nevertheless, within this case (chronic
nonspeciﬁc low back pain), there were no large differences
between these countries and The Netherlands in patient popula-
tion and in their main health-care characteristics. The health care
for patients with chronic low back pain is largely comparable
between the study countries, therefore, the practice variation and
the technology availability is limited. Next to that, the Dutch
prices were used for the calculations of the predictions. The
relevant population characteristics for this case, incidence/
prevalence; case-mix; health-status preference; acceptance, com-
pliance, and incentives to patients; and productivity and work-
loss time are, with the exception of the last criterion, practically
the same between the study countries. The health care and popu-
lation characteristics are, therefore, less important in this study,
because of the similarities between the countries [6].
Six of the seven studies were, partially, transferable to The
Netherlands. The study of Skouen et al. (2002) was not transfer-
able because of differences in perspective, medical cost approach,
and because of problems with the data extraction [41].
The foreign studies were divided into two different groups.
All studies that did not pass the general knockout criteria or the
speciﬁc knockout criteria are in group 1. The second group
comprises the studies that are considered to be transferable to
The Netherlands. In the “all studies prediction,” the results of
group 1 are included and in the “Welte’s model prediction,” the
studies included in group 2 were used.
Comparing Predictions
The results of the “all studies prediction,” the “Welte’s model
prediction,” and the Dutch reference study (Van der Roer, 2008)
[12] were compared with each other. The results are presented in
Table 5.
It is evident that the cost estimations between the two pre-
dictions differ. In the “all studies prediction,” the highest costs
were for the physiotherapy group and this was caused by the high
Determination of the case 
Search for articles 
Determine which data are 
needed to make the 
predictions with help of 
guideline of Oostenbrink 
Use foreign 
quantities and 
Dutch prices 
Apply general knockout criteria
Make “all 
studies 
prediction” 
and
perform 
sensitivity
analysis 
Apply specific
knockout criteria
Use foreign 
quantities and 
Dutch prices 
Make
“Welte’s 
model
prediction” 
and perform 
sensitivity
analysis 
Compare the two predictions with each other and with the 
results of the Dutch reference study 
Figure 1 Flowchart of the method.
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costs of sick leave. The average number of days of sick leave was
32.3 days in the physiotherapy group, and in the other predic-
tion, this was 10.3 days. This high average in the physiotherapy
group was caused by the study of Torstensen et al. [39], which
reported a high number of days of sick leave. As a result, the
average days of sick leave were high and this also inﬂuenced
the total costs for the physiotherapy group substantially. In the
“Welte’s model prediction,” the highest total costs were for
the multidisciplinary treatment group. The treatment costs of the
multidisciplinary treatment were higher than the costs of phys-
iotherapy in this prediction. This could be explained by the
intensity of the multidisciplinary treatment and the staff needed.
The difference in effect, expressed in QALYs, between the two
treatment options was rather large in the “Welte’s model predic-
tion,” namely 0.21 QALYs in favor of the physiotherapeutic
treatment. In the “all study prediction,” the difference was 0.04
in favor of the physiotherapy group. In the sensitivity analyses,
the differences in QALYs ranged from -0.26 to 0.11.
In the Dutch study, the multidisciplinary treatment was more
effective, but also more expensive. The ICER was favorable for
the multidisciplinary treatment, but this was mainly caused by a
small difference in costs.
In the next step, the “all studies prediction” and the “Welte’s
model prediction” were compared with the Dutch study. The
difference in effect was high, namely -0.04 for the “all studies
prediction” and -0.21 for the “Welte’s model prediction” versus
0.03 for the Dutch study. The cost differences in the predictions
were larger than in the Dutch results. For the “all studies predic-
tion,” the difference in costs was €-5266 in favor of the multi-
disciplinary treatment, and in the “Welte’s model prediction,”
the difference was €2490, whereas in the Dutch study, it was
€233. The main reason for the differences in costs between the
predictions and the Dutch results was the higher costs of the
multidisciplinary treatment in the predictions, whereas in the “all
studies prediction,” the costs of sick leave in the physiotherapy
group were much higher.
The results in Figure 2 indicate the differences in total costs of
the two treatment groups between the two predictions and the
Dutch study. The highest correspondence concerning the total
costs for the multidisciplinary treatment is between the “all
studies prediction” and the Dutch study. The total costs by the
“Welte’s model prediction” are just outside the conﬁdence inter-
val of the Dutch study. For physiotherapy, the results are differ-
ent. In this case, the total costs of the physiotherapy group by the
“Welte’s model prediction” is almost comparable with the total
costs in the Dutch study. The total costs by the “all studies
prediction” are considerably higher than that of the “Welte’s
model prediction” and the Dutch study.
Discussion
Model of Welte
The two predictions differ in both the costs and effect estimations
of the multidisciplinary treatment and physiotherapy. Using
Welte’s model yield better results for the cost prediction than
when the foreign results are applied straightforward in the deci-
sion country, but the effectiveness prediction was less accurate.
Because of the differences between the “all studies prediction”
and the “Welte’s model prediction,” it can be concluded that
Welte’s model does inﬂuence the ﬁnal results. The differences
between the “all studies” and the “Welte’s model prediction” are
caused by both the general and speciﬁc knockout criteria. Seven
studies were deleted by the general knockout criteria and mainly
by the third criterion (ﬁve out of seven studies), and one study by
the speciﬁc knockout criteria. The “Welte’s model prediction”Ta
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was better in the costs estimations than the “all studies predic-
tion,” because the estimation was more alike the Dutch results.
Nevertheless, the “all studies prediction” had the highest
correspondence with the Dutch results concerning the effects
estimation.
In this case, the general knockout criteria had the most inﬂu-
ence on the transferability of studies. It seems that if a study has
a good methodological quality, the chance increases that the
study is transferable. Another ﬁnding is that the model focuses
mainly on the transferability of costs.
Difﬁculties Encountered during the Making of
the Predictions
The ﬁrst difﬁculty with making the current predictions was the
diversity among the multidisciplinary treatments as described in
the foreign studies. Therefore, some variation could be observed
between the foreign studies and also between the foreign studies
and the reference study. This difﬁculty will occur in almost every
treatment, which is caused by small differences in deﬁnition and
practice variation between settings.
The second difﬁculty occurred with the parameters “medi-
cine” and “imaging techniques.” This difﬁculty is inﬂuenced by
two problems. The ﬁrst was the availability of the data on these
two parameters, and the second is the large practice variation
between countries. In the available data, it was unclear which
drug was prescribed or which imaging technique was used.
Therefore, it was not possible to value these parameters at the
right prices. Furthermore, it is known that large practice varia-
tions exist between countries, for example, in drug prescriptions
and standard of care. As a consequence, it was decided to exclude
these parameters from the predictions.
Table 5 (a) Recalculation of costs using Dutch prices
Cmdt* Cphysio* Csl* Ch* E
International Studies
Studies not passing knockout criteria (group 1)
Cherkin (2001) [32] 100 — 31
Cherkin (1998) [33] — 162
Karjalainen [34,35] 154 — 294 0.88
Klaber Moffet [36] — 185 1537 259 0.77
Molde Hagen [37,38] 154 — 12
Torstensen [39] — 833 32508
Wright [40] 251 —
Skouen [41] 3670 —
Transferable studies (group 2)
Brown [42] 1257 — 2244
Fairbank [43] & Rivero-Arias (2005) [44] 4442 — 132 0.48
Frost [45] & Rivero-Arias (2006) [46] — 111 2698 87 0.74
Kääpä [47] MDT 4402 — 2533
physio — 463 3150
Skargren [48] — 148 40
UK BEAM [49,50] — 218 141 0.64
Predictions (base-case)
All studies prediction MDT 1804 — 2388 216 0.68
(group 1) physio — 303 9186 185 0.72
Welte’s model prediction MDT 3367 — 2388 132 0.48
(group 2) physio — 351 2925 121 0.69
*All prices in 2004 euros in The Netherlands.
Cmdt, costs multidisciplinary treatment; Cphysio, costs physiotherapy; Csl, costs of sick leave; Ch, costs of health care consumption; E, effect of treatment.
Table 5 (b) Results of the two predictions and the Dutch study
Cmdt* Cphysio* Csl* Ch* DC E DE
Predictions (base-case)
All studies prediction MDT 1804 — 2388 216 -5266 0.67 -0.04
(group 1) physio — 303 9186 185 0.72
Welte’s model prediction MDT 3367 — 2388 132 2490 0.48 -0.21
(group 2) physio — 351 2925 121 0.69
Sensitivity analysis
All studies prediction high MDT 4442 — 2533 303 -26.419 0.88 0.11
(group 1) physio — 833 32508 356 0.77
low MDT 100 — 2244 76 685 0.48 -0.16
physio — 111 1537 83 0.64
Welte’s model prediction high MDT 4442 — 2533 132 3323 0.48 -0.26
(group 2) physio — 463 3150 171 0.74
low MDT 1257 — 2244 132 741 0.48 -0.16
physio — 111 2698 83 0.64
Dutch study
Van der Roer [12] MDT 779 — 2806 307 233 0.03
physio — 312 2933 412
*All prices in 2004 euros in The Netherlands.
Cmdt, costs multidisciplinary treatment; Cphysio, costs physiotherapy; Csl, costs of sick leave; Ch, costs of health care consumption; E, effect of treatment.
Testing the Model of Welte 735
The third difﬁculty is that an additional test of the Welte
criteria would have been comparing studies that pass versus
those that do not pass the speciﬁc knockout criteria, while
excluding all those not passing the general knockout criteria. A
supplementary comparison, in this study, could be solely with the
studies that did not pass the speciﬁc knockout criteria. This
comparison indicates the importance of the speciﬁc knockout
criteria. Nevertheless, by this case, only one study did not pass
these criteria. Therefore, the preferred comparison gave no or not
much extra information compared with the two current included
predictions.
Problems and Recommendations Concerning
Welte’s Model
The main problem of Welte’s model, within this study, is that
only the methodological characteristics could be assessed
without using extra information outside the articles. A large
problem when transferring studies is the complexity of judging
the health care and population characteristics. This extra infor-
mation was not readily available. These characteristics and their
corresponding factors are often not stated in the articles. The
transferability literature [2–4] reveals that there is enough reason
to believe that these factors inﬂuence the transferability of eco-
nomic evaluations. Nevertheless, in this case, the health care and
population characteristics were not applied, because of the high
similarity between the study countries and the decision country.
The population and the health-care system corresponded sufﬁ-
ciently between the countries and, therefore, it was not consid-
ered necessary to correct these characteristics.
The third general knockout criterion states that the study
should possess an acceptable quality, but it is not clear how the
quality should be assessed by Welte [6]. Some common quality
criteria for economic evaluations, like perspective and discount
rate, are now used as transferability factors. Nevertheless, it is
known that between countries, the guidelines for economic
evaluations and the quality criteria differ. By stating general
quality criteria, this criterion will become clearer.
Another problem of Welte’s model is the overlap between
some of the factors, for instance between the factors “practice
variation” and “technology availability” or “medical cost
approach” and “absolute and relative prices.” As a consequence,
it is harder to assess these factors. This makes it more difﬁcult to
use Welte’s model.
The last problem deals with the lack of attention for the
transferability of effects. Almost all speciﬁc knockout criteria
discuss the transferability of cost parameters. Only the criterion
“health-status preference” focuses solely on the transferability of
effects. Nevertheless, some criteria have an inﬂuence on both
costs and effects. Furthermore, more attention should be given to
how and with which instrument the effects are measured in a
study, because this could inﬂuence the effect parameter. It is
known from the literature that the valuation of health states and
the instruments used vary from country to country [51]. There-
fore, this should be taken into account when transferring effect
data to other countries. This could be a new factor in an
improved version of Welte’s model.
At this moment Welte’s model is mainly focused on the idea
to assess the transferability of whole studies. In the case that a
study as a whole is not transferable, it could be that a study
section is still usable. Therefore, a second option to improve
Welte’s model is to give more attention to the possibility to assess
the transferability of a section or sections of a study. By making
it easier to assess the transferability of sections of studies, more
information might be available to calculate a prediction for the
decision country.
Implications of the Results
Welte et al. (2004) [6] stated that it is possible to transfer data to
other settings, but the results were not compared with data from
the decision country. The results of this study indicate that it is
feasible to transfer data to The Netherlands. Nevertheless, more
case studies should be subjected to Welte’s model before a ﬁnal
conclusion can be drawn. In this study, it was difﬁcult to distin-
guish the effects of the general knockout from the effects of the
speciﬁc knockout criteria. By this case, it is not clear why most
studies passing the general knockout criteria also passed the
speciﬁc knockout criteria. It is not clear whether this is because of
this speciﬁc case. Therefore, this needs to be clariﬁed by applying
Welte’s model to another case. The results of one case study, as
presented in this article, is too limited to draw ﬁnal conclusions
on the functioning of Welte’s model.
In addition, Welte’s model is not the only existing model to
assess the transferability of economic evaluations. Boulenger
et al. [3], Urdahl et al. [9], and Nixon et al. [10] are all published
methods that, by using a checklist, try to assess the transferability
of studies. By the method of Boulenger et al., the answers to the
0
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questions lead to transferability information score [3]. Nixon
et al. have developed a method that is related to that of Bou-
lenger. The economic evaluations are assessed with the help of a
questionnaire that is based on the guidelines from BMJ [9].
Nevertheless, it is hard to determine what these scores indicate,
because no standards are available. The method of Urdahl et al.
is developed for decision-analytic models to assess whether
articles provide enough information to decision-makers [9]. A
combination of the Welte and Boulenger methods is suggested by
Antoñanzas et al. [52]. The principle of general knockout
criteria is adopted from Welte, but the scoring system and the
questions are based on Boulenger [52]. Nixon et al. is a supple-
mentary article on the method of Boulenger whereby some points
of criticisms are discussed [53]. Nevertheless, the interpretation
of the scoring remains unclear. Given these recent developments,
the next step will be to test the applicability of the methods of
Boulenger [3,53] and Antoñanzas [52].
To improve Welte’s model, additional research on the trans-
ferability of effects and on other transferability factors is needed.
At the moment, it is considered that effects are comparable in all
countries, but more research is needed in this ﬁeld [51]. Further-
more, in the literature [2–4], several transferability factors are
listed, but it is yet unknown which factors have the most inﬂu-
ence. When this is known, it will be easier to develop a new
method for determining the transferability of economic evalua-
tions. Welte’s model could then be used as a template. Welte’s
model worked reasonably well in this case, but improvements are
necessary to make the model easier to use.
Source of ﬁnancial support: No funds were received to support this work.
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